Patent application number | Description | Published |
20080269583 | Detection and Monitoring of Stress Events During Sleep - A computer-implemented method for monitoring a patient ( | 10-30-2008 |
20080300500 | APNEA DETECTION USING A CAPNOGRAPH - A method for diagnosis includes receiving a signal indicative of a partial pressure of CO | 12-04-2008 |
20110054279 | DIAGNOSIS OF PERIODIC BREATHING - A method for diagnosis comprises receiving a signal associated with respiration of a patient. The signal is processed so as to identify features that are indicative of beginning and end times of apnea episodes. Time shifts between recurrences of the features are computed and processed so as to generate an output comprising a plurality of bands corresponding to different multiples of a cycle length of the apnea episodes. | 03-03-2011 |
20120179389 | Gas Chromatographic Analysis Method and System - Method employing gas chromatography for determining a measure of match between chromatographic data respective of a sample and reference data, the method includes the procedures of acquiring the chromatographic data, determining a plurality of parameters in a modeling function so as to substantially fit the modeling function to the chromatographic data, the modeling function defined as a sum of a linear combination of probability distribution functions, and estimating the measure of match according to a degree of fitness between the modeling function and the chromatographic data. | 07-12-2012 |
20150031979 | DERIVING INDIVIDUAL THORACIC PARAMETERS OF A SUBJECT - A method of deriving one or more individual thoracic parameters of a subject. The method comprises instructing a subject to perform a thoracic volume manipulation, receiving a plurality of measurements of a plurality of EM signals from a thoracic intrabody area of lungs of the subject during the thoracic volume manipulation, deriving a plurality of thoracic volume values at a plurality of different intervals during the thoracic volume manipulation so that each the thoracic volume value correspond with another of a plurality of estimated thoracic volumes achieved during the thoracic volume manipulation, and calculating at least one individual thoracic parameter of the subject by combining between the plurality of measurements and the plurality of thoracic volume values. | 01-29-2015 |
Patent application number | Description | Published |
20090060864 | Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies - The invention provides methods for treating tumors and tumor metastases in a mammal comprising administering, to a mammal in need of treatment, a therapeutic amount of an antagonist sufficient to inhibit angiogenesis in combination with a therapeutic amount of anti-tumor immunotherapeutic agent, such as a anti-tumor antigen antibody/cytokine fusion protein having a cytokine and a recombinant immunoglobulin polypeptide chain sufficient to elicit a cytokine-specific biological response. | 03-05-2009 |
20090253778 | DNA composition against tumor stromal antigen FAP and methods of use thereof - A DNA composition effective for eliciting an immune response against tumor cells and tumor metastases comprising a DNA construct that encodes for at least one epitope of fibroblast activation protein (FAP), which is expressible in immune cells, and which is incorporated in a pharmaceutically acceptable carrier. The composition can encode a single epitope of FAP, a polypeptide comprising two or more epitopes of FAP, the entire FAP protein, or any portion thereof that will elicit the desired immune response. In one preferred embodiment, the composition also includes a DNA construct that encodes an immune effector protein, such as a cytokine. The DNA composition of the invention can be used alone or in combination with a chemotherapeutic agent to treat diseases such as tumors and tumor metastases. | 10-08-2009 |
20090275642 | DNA COMPOSITION FOR ELICITING AN IMMUNE RESPONSE AGAINST TUMOR-ASSOCIATED MACROPHAGES - The present invention provides a DNA composition comprising a DNA minigene construct that encodes for a polypeptide comprising a plurality of immunogenic fragments of a cysteine endopeptidase that is expressed in tumor-associated cells. The immunogenic fragments are joined together serially by a linker peptide between each successive fragment in the polypeptide. The polypeptide is capable of eliciting an immune response against the tumor-associated cells, is expressible in immune cells, and is incorporated in a pharmaceutically acceptable carrier. | 11-05-2009 |
20100136058 | DNA vaccines against tumor growth and methods of use thereof - A DNA vaccine suitable for eliciting an immune response against cancer cells comprises a polynucleotide construct operably encoding an a Fra-1 protein, such as a polyubiquitinated human Fra-1 protein, and IL-18, such as human IL-18, in a pharmaceutically acceptable carrier. In a preferred embodiment, the polynucleotide construct is operably incorporated in an attenuated bacterial vector, such as an attenuated | 06-03-2010 |
20120039931 | DNA COMPOSITION ENCODING AN IMMUNOGENIC VEGF RECEPTOR PEPTIDE AND METHODS OF USE THEREOF - A method of inhibiting endothelial cell proliferation in a mammal is provided. The method comprises the step of administering to the mammal an effective immunological response eliciting amount of a DNA composition comprising a DNA construct operably encoding a VEGF receptor polypeptide and a pharmaceutically acceptable carrier therefor, whereby said mammal exhibits an immune response elicited by vaccine and specific to proliferating endothelial cells. The methods of this invention inhibit vascular endothelial cell proliferation in the tumor micro-environment. Angiogenesis inhibition and subsequent decrease in tumor growth and dissemination is achieved. | 02-16-2012 |
20140322249 | DNA VACCINES AGAINST TUMOR GROWTH AND METHODS OF USE THEREOF - A DNA vaccine suitable for eliciting an immune response against cancer cells comprises a DNA construct operably encoding a cancer-associated Inhibitor of Apoptosis-family protein and an immunoactive gene product, such as a cytokine or a ligand for a natural killer cell surface receptor, in a pharmaceutically acceptable carrier. A preferred cytokine is CCL21. Preferred ligands for a natural killer cell surface receptor include human MICA, human MICB, human ULBP1, human ULBP2, and human ULBP3. The cancer-associated Inhibitor of Apoptosis (IAP)-family protein is preferably a survivin protein or livin protein. Method of inhibiting tumor growth by administering the vaccine of the invention to a mammal is also described. | 10-30-2014 |